共 50 条
Restless legs syndrome—current therapies and management of augmentation
被引:0
|作者:
Claudia Trenkwalder
Juliane Winkelmann
Yuichi Inoue
Walter Paulus
机构:
[1] Paracelsus Elena Klinik,Department of Neurosurgery
[2] Centre of Parkinsonism and Movement Disorders,Department of Clinical Neurophysiology
[3] Kassel,Department of Neurology and Neurological Sciences and Centre for Sleep Sciences and Medicine
[4] University Medical Centre Göttingen,Department of Somnology
[5] University Medical Centre Göttingen,undefined
[6] Stanford University,undefined
[7] Neurologische Klinik und Poliklinik,undefined
[8] Klinikum rechts der Isar,undefined
[9] Technische Universität München,undefined
[10] Japan Somnology Center,undefined
[11] Neuropsychiatric Research Institute,undefined
[12] Tokyo Medical University,undefined
来源:
关键词:
D O I:
暂无
中图分类号:
学科分类号:
摘要:
Treatment of restless legs syndrome (RLS) usually involves dopamine agonists, which are approved for treatment of RLS in most countries; α-2-δ ligands, such as gabapentin enacarbil and pregabalin, are also effectiveIn patients with RLS who have low levels of ferritin, iron supplementation should be the first-line therapyFor patients with severe RLS, opioids such as oxycodone–naloxone are an option as second-line therapy where they are approvedAugmentation is a major complication of long-term RLS therapy with dopaminergic agents, and is related to high doses of dopaminergicsInternational treatment guidelines recommend weighing the benefits against the risks for each drug class when initiating treatmentCombined treatment approaches are used on the basis of expert opinions, and are currently not evidenced-based
引用
收藏
页码:434 / 445
页数:11
相关论文